Bio Break: How Nature-Inspired Biosensors Are Revolutionizing Medical Devices
In this episode of Bio Break, Nick and Joris dive into the fascinating realm of biosensors, showcasing how nature’s biological processes inspire groundbreaking innovations in medical device technology. From jellyfish to fireflies, the natural world has provided invaluable tools that are transforming diagnostics and research.
The discussion kicks off with green fluorescent protein (GFP), a revolutionary biosensor derived from jellyfish. Discovered in the 1960s and popularized in the 1990s, GFP earned its place in history with a Nobel Prize. This remarkable protein fluoresces when exposed to specific wavelengths of light, enabling scientists to monitor cellular activities. GFP has become an indispensable tool for tracking cellular processes, from observing metabolic activities to measuring changes in pH levels. Joris shares an example from his PhD research, where he utilized a modified GFP to measure the redox state of cells, highlighting the protein’s adaptability and utility.
The conversation shifts to luminescence, drawing inspiration from fireflies and their ability to emit light through biochemical reactions. This phenomenon, known as bioluminescence, has been harnessed in medical research to create biosensors that can emit light when specific chemical reactions occur. Joris discusses how luminescent molecules, such as luciferase, have played pivotal roles in cancer research and diagnostics. A newer innovation, NanoLuc, inspired by deep-sea shrimp, has taken luminescence to the next level with its smaller, brighter design, enabling more efficient and precise applications.
This episode highlights how the interplay of biology and engineering continues to unlock new possibilities in diagnostics and medical devices. By mimicking nature’s ingenuity, biosensors are paving the way for non-invasive, accurate, and efficient tools for understanding and monitoring health.
Related Resources
Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.
Nigel Syrotuck breaks down the realistic medical device V&V cost and schedule for terminally sterilized devices, picking up after design freeze and walking through each major phase of the process.